Ardsley Advisory Partners »

Rapt Therapeutics shares owned by Ardsley Advisory Partners

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by Ardsley Advisory Partners from 13F filings

Historical chart of Ardsley Advisory Partners investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by Ardsley Advisory Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by Ardsley Advisory Partners

Quarter filed Position value Share count Share price at filing
2024-03-31 $3.6M 403k 8.98

More positions owned by Ardsley Advisory Partners

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Sunrun (RUN)
Celestica Sub Vtg Shs
Sunopta (STKL)
Itron (ITRI)
Bioceres Crop Solutions Corp SHS (BIOX)
Hannon Armstrong (HASI)
Oscar Health Cl A (OSCR)
Fluor Corporation (FLR)
Ftai Aviation SHS (FTAI)
Aspen Aerogels (ASPN)
Pacira Pharmaceuticals (PCRX)
Sentinelone Cl A (S)
Ferroglobe SHS (GSM)
Spdr Gold Tr Gold Shs (GLD)

View all positions for Ardsley Advisory Partners

Top funds holding Rapt Therapeutics

Vanguard Group
Column Group
BlackRock
BlackRock
Kingdon Capital Management
Morgan Stanley
D. E. Shaw & Co
Acadian Asset Management
Federated Investors
Two Sigma Advisers
Geode Capital Management
State Street Corporation
Euclidean Capital
Two Sigma Investments
Alphabet

View all funds holding Rapt Therapeutics